Verdict No. 3068 · Search date 2026-09-08 · Methodology v1.0
Oral single-ingredient berberine,
does it really help with Reduction of LDL-C in adults with dyslipidemia?
30-Second Summary
C
Evidence Grade C · 50 · Safety warning
This verdict covers short-term LDL-C with single-ingredient berberine; cardiovascular events remain separate.
Warning. Gastrointestinal adverse effects may be more frequent than placebo, and lipid-lowering medicine should not be replaced without care. Pregnancy, lactation, infancy, and CYP-related concomitant medicines require clinical review.
What the
research showsGrade C with 50 points. Across 14 placebo RCTs and 1,447 participants, pooled LDL-C was -0.46 mmol/L (95% CI -0.62 to -0.30). Yet the 12-week difference in an 84-man trial was null at -0.21 mmol/L (-0.50 to 0.08; P=.15), while a 2026 trial in 100 women was positive, leaving directional and population heterogeneity.
research showsGrade C with 50 points. Across 14 placebo RCTs and 1,447 participants, pooled LDL-C was -0.46 mmol/L (95% CI -0.62 to -0.30). Yet the 12-week difference in an 84-man trial was null at -0.21 mmol/L (-0.50 to 0.08; P=.15), while a 2026 trial in 100 women was positive, leaving directional and population heterogeneity.
What the
ads claimDo not claim statin replacement, cardiovascular-event prevention, or merge triglyceride and HDL results into the LDL claim.
ads claimDo not claim statin replacement, cardiovascular-event prevention, or merge triglyceride and HDL results into the LDL claim.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Berberine hydrochloride, botanical extracts, combination formulas, dihydroberberine, other derivatives, and topical products are not interchangeable.
- Warning. Gastrointestinal adverse effects may be more frequent than placebo, and lipid-lowering medicine should not be replaced without care. Pregnancy, lactation, infancy, and CYP-related concomitant medicines require clinical review.
Chamgap Semantic Classification Code
Permanent code issued
S.berberine.oral.ldl-cholesterol.reduce.placeboSupplements and nutraceuticals > Single-ingredient berberine > Oral > LDL cholesterol > Reduction claim > Placebo
Bound to short-term LDL-C in single-ingredient placebo trials; triglycerides, HDL, weight, cardiovascular events, and combination nutraceuticals are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Berberine |
| Source or part used | Purified alkaloid from berberine-containing plants; source varied or was unverified across trials |
| Formulation or processing | Single-ingredient berberine tablets or capsules; combination nutraceuticals excluded |
| Route | Oral |
| Dose | Mostly 900-1,500 mg/day |
| Duration | 4-24 weeks |
| Population | Adults with dyslipidemia, generally at low cardiovascular risk |
| Effect or condition | Lower LDL-C |
| Primary endpoint | Absolute between-group LDL-C difference at treatment end |
| Comparator | Placebo |
| Duplicate-detection key | Berberine|Single-ingredient berberine tablets or capsules; combination nutraceuticals excluded|Oral|Adults with dyslipidemia, generally at low cardiovascular risk|Lower LDL-C|4-24 weeks |
Gap Measurement · Verdict 3068 · C 50
What the research actually shows
The CRD42021293218 meta-analysis, NCT03770325 men's trial, and NCT06782646 women's trial were cross-checked; combination products and Berberis extracts were excluded.
Why this is classified as C (50)
Axes are S/R0/I2/EX/B2/CX. I2 is one strength, but surrogate LDL, sex/analysis conflict, uncertain LDL-primary confirmation, and short small trials yield C/50.
Counterpoint. LDL was null in the 84-man trial and positive in the 2026 100-woman trial, but the reports share investigators and apoB was the women's prespecified primary outcome. They were not counted as two independent LDL confirmations.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R0 | Trials conflict in direction |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 1,788 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
| Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 84 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
| Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 84 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
| Effects of berberine on lipid profile in subjects with low cardiovascular risk | Design, allocation, masking, endpoint hierarchy, and analysis set were independently checked. | 144 | Funding, product support, employee authorship, and conflicts were assessed separately. | The principal endpoint contract is preserved; other outcomes remain separate. | Verified estimates are preserved; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, hierarchy, and reporting limitations. |
Receipt — 4 References
Of 4 cited sources, 1 had limited original-page access (blocked or summary-only) and were verified via index/summary, marked partial; the rest were verified at the original page. As of 2026-09-08.
Blais JE et al. Drugs. 2023. PMID: 36941490. DOI: 10.1007/s40265-023-01841-4. PROSPERO: CRD42021293218.
checkedChan YH et al. Nutrients. 2021;13:2550. PMCID: PMC8401658. DOI: 10.3390/nu13082550. NCT03770325.
checkedZhao JV et al. JACC Asia. 2026. PMID: 42470424. DOI: 10.1016/j.jacasi.2026.06.011. NCT06782646/NCT03770325.
checkedDerosa G et al. Expert Opin Biol Ther. 2013. PMID: 23441841. DOI: 10.1517/14712598.2013.776037.
partialResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Berberine for LDL Cholesterol—A Positive 14-Trial Meta-Analysis, but Direct 12-Week Results Varied by Sex and Analysis — Evidence Grade C·50. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-berberine-dyslipidemia-ldl-cholesterol/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.